Abstract 530P
Background
Recent evidence have showed that high level of systemic inflammation is associated with poor survival in patients with malignancy by promoting cell proliferation. Inflammation-based serum biomarkers including C Reactive Protein (CRP), Albumin (ALB) and CRP/ALB ratio have been showed to have prognostic value in patients with Small Cell Lung Cancer (SCLC). C-reactive protein (CRP) is a nonspecific serum marker of acute-phase inflammatory response. Studies have hypothesized that High CRP is a surrogate marker of tissue inflammation secondary to tumor growth. Albumin is both an inflammatory and nutritional marker. They are readily available and cost-effective tests that are potential prognostic biomarkers and therapeutic targets. Prognostic biomarkers help to optimize therapy decisions, as they provide information on the likelihood of response to a given chemotherapeutic regimen.
Methods
The databases of PubMed, Cochrane, and Google Scholar were systematically searched until July 2019. Associations between CRP, ALB and CRP/ALB ratio and overall survival (OS) were investigated by pooling hazard ratio (HR) and 95% confidence interval (CI).
Results
A total of 13 studies comprising of 2,034 patients were included. The results showed that only High CRP (HR 1.36, CI 95% 1.01, 1.82 p = 0.04) and High CRP/ALB (HR 1.38, CI 9%% 1.15, 1.64 p = 0.0004) ratio are significantly associated with overall survival. Albumin has no statistical association with OS.
Conclusions
High CRP and CRP/ALB ratio are independent prognostic biomarkers in patients with SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract